ClinicalTrials.gg
CompletedNCT05238675Updated Jul 28, 2026

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

A Phase 2 interventional study of BI 1291583 and Placebo in Bronchiectasis, sponsored by Boehringer Ingelheim. Completed at 112 sites in 23 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Enrollment
10th of 52
322 · median 78
Started
2022
with 2 others
Phase 2
15 of 65
4 open now
Registered
40th of 65
by date
Lead sponsor
5 of 65
Boehringer Ingelheim

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 10th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2022, is one of 15 in phase 2, and was the 40th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations).

The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis.

Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day.

Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff.

The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Bronchiectasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Male or female patients: Women of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the patient information.

Men participating in this clinical trial must use male contraception (condom or sexual abstinence) if their sexual partner is a WOCBP.

  • Signed and dated written prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation.
  • Age of patients when signing the informed consent ≥18 (for Korea: ≥19) and ≤85 years.
  • Clinical history consistent with bronchiectasis (e.g., cough, chronic sputum production and/or recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by computed tomography (CT) scan. Subjects whose past chest radiographic image records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than 5 years.
  • History of pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, patients must have had either:

    • at least 2 exacerbations, or
    • at least 1 exacerbation and a St. George´s Respiratory Questionnaire (SGRQ) Symptoms score of >40 at screening visit 1.

For patients on stable oral or inhaled antibiotics as chronic treatment for bronchiectasis, at least one exacerbation must have occurred since initiation of stable antibiotics.

- Current sputum producers with a history of chronic expectoration who are able to provide a spontaneous (not induced) sputum sample at Screening Visit 1.

Exclusion criteria

Exclusion Criteria:

Laboratory and medical examination

  • (AST) and / or Alanine Aminotransferase (ALT) >3.0 x (ULN) at Visit 1, or moderate or severe liver disease (defined by score B or C hepatic impairment).
  • Estimated (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \< 30 mL/min at Visit 1.
  • An absolute blood \<1,000/mm\^3 at Visit 1 (equivalent to \<1,000 cells/µL or \<109 cells/L).
  • Any findings in the medical examination and/or laboratory value assessed at Screening Visit 1 or during screening period, that in the opinion of the investigator may put the patient at risk by participating in the trial.
  • Positive serological tests for , , or (HIV) infection, or known infection status.

Concomitant diagnosis and therapy

  • A current diagnosis of:

    • Cystic Fibrosis
    • Hypogammaglobulinemia
    • Common variable immunodeficiency
    • α1-antitrypsin deficiency being treated with augmentation therapy
    • Allergic bronchopulmonary aspergillosis being treated or requiring treatment
    • Tuberculosis or non-tuberculous mycobacterial infection being treated or requiring treatment according to local guidelines
    • Palmoplantar keratosis; or keratoderma climactericum
    • Hypothyroidism, myxedema, chronic lymphedema with associated hyperkeratosis of the skin, acrocyanosis. If a subject has hypothyroidism but is treated and compensated, the subject is allowed into the trial
    • Psoriasis affecting palms and soles; or body surface area for psoriasis ≥ 10%
    • Reactive arthritis (Reiter's syndrome); keratoderma blennorrhagicum
    • Pityriasis rubra pilaris
    • Atopic dermatitis affecting palms and soles; or body surface area for atopic dermatitis ≥ 10%
    • Active extensive verruca vulgaris, as per investigator's discretion
    • Active fungal infection of hand and/or feet not adequately treated, or not responsive to antifungal therapy, as per investigator's discretion.
  • Any (at the discretion of the investigator) acute respiratory infection within 4 weeks prior Visit 2, or any other acute infection requiring systemic or inhaled anti-infective therapy within 4 weeks prior Visit 2.
  • Any evidence of a concomitant disease, such as Papillon-Lefevre Syndrome, relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal disorders, or patients who are with a higher risk of invasive pneumococcal disease or other invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis), that in the opinion of the investigator, may put the patient at risk by participating in the study.
  • Received any within 4 weeks prior to Visit 2.
  • Medical conditions associated with periodontal disease (to be evaluated by a periodontist or dentist):

    • Any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before the study (e.g. pulp necrosis).
    • Severe periodontal disease defined as with pocket depth measurements ≥ 6 mm on 2 or more teeth.
    • Class-3 mobility or Class-3 furcation involvement.
    • Scheduled tooth extraction during the study period.
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.

Further exclusion criteria apply

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    BI 1291583: Low dose group

    Drug: BI 1291583

  • Experimental
    BI 1291583: Medium dose group

    Drug: BI 1291583

  • Experimental
    BI 1291583: High dose group

    Drug: BI 1291583

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • BI 1291583

    Also known as: Verducatib

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Time to first pulmonary exacerbation up to 48 weeks after first drug administration

    Time frame: Up to week 48

Secondary outcomes

  1. Key secondary: Rate of pulmonary exacerbations (number of events per person-time) up to week 48 after first drug administration

    Time frame: Up to week 48

  2. Absolute change from baseline in Quality of Life Questionnaire - Bronchiectasis (QOLB) respiratory symptoms domain score at week 24 after first drug administration

    Time frame: At baseline and at week 24

  3. Relative change from baseline in neutrophil elastase (NE) activity in sputum at week 12 after first drug administration

    Time frame: At baseline and at week 12

  4. Absolute change from baseline in St. George's Respiratory Questionnaire (SGRQ) Symptoms score at week 24 after first drug administration

    Time frame: At baseline and at week 24

  5. Absolute change from baseline in percent predicted post-bronchodilator forced expiratory volume in one second (FEV1%pred) at week 24 after first drug administration

    Time frame: At baseline and at week 24

  6. Occurrence of an exacerbation by week 24 after first drug administration

    Time frame: Up to week 24

07

Study locations

112 sites
  • Phoenix Medical Group
    Peoria, Arizona 85381, United States
  • Newport Native MD, Inc
    Newport Beach, California 92663, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • Central Florida Pulmonary Group
    Altamonte Springs, Florida 32701, United States
  • Malcom Randall VA Medical Center
    Gainesville, Florida 32608, United States
  • University of Florida College of Medicine
    Jacksonville, Florida 32209, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • NewYork-Presbyterian/Weill Cornell Medical Center
    New York, New York 10065, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Institute for Translational Oncology Research
    Greenville, South Carolina 29605, United States
  • Metroplex Pulmonary & Sleep Center
    McKinney, Texas 75069, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • University of Texas Health Science Center at Tyler
    Tyler, Texas 75708, United States
  • Macquarie University
    North Ryde, New South Wales 2109, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Lung Research Queensland
    Chermside, Queensland 4032, Australia
  • Mater Research Institute
    South Brisbane, Queensland 4101, Australia
  • Institute for Respiratory Health
    Nedlands, Western Australia 6009, Australia
  • Trialswest
    Spearwood, Western Australia 6153, Australia
  • UNIV UZ Gent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Medical Center "Zdrave-1"
    Kozloduy, 3320, Bulgaria
  • Medica Center Hera - Montana Branch
    Montana, 3400, Bulgaria
  • Medical Center ReSpiro Ltd
    Razgrad, 7200, Bulgaria
  • SHATPFD "Dr. Dimitar Gramatikov"
    Rousse, 7002, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • Jewish General Hospital
    Montreal, Migration Data H3T 1E2, Canada
  • Centre Hospitalier de l'Universite de Montreal (CHUM)
    Montreal, Quebec H2X 0A9, Canada
  • IUCPQ (Laval University)
    Québec, Quebec G1V 4G5, Canada
  • Pulmonary Private Practice Kralupy
    Kralupy nad Vltavou, 27801, Czechia
  • The First Pulmonary Private Practice
    Prague, 19000, Czechia
  • Aalborg Sygehus Syd
    Aalborg, 9000, Denmark
  • Hvidovre Hospital
    Hvidovre, 2650, Denmark
  • Copenhagen University Hospital, Rigshospitalet
    København Ø, 2100, Denmark
  • Odense University Hospital
    Odense, 5000 C, Denmark
  • Sjællands Universitetshospital
    Roskilde, 4000, Denmark
  • Vejle University Hospital
    Vejle, 7100, Denmark
  • HOP Amiens-Picardie Sud
    Amiens, 80054, France
  • HOP Arnaud de Villeneuve
    Montpellier, 34295, France
  • HOP Cochin
    Paris, 75679, France
  • HOP Pontchaillou
    Rennes, 35033, France
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, 45239, Germany
  • IKF Pneumologie GmbH & Co. KG
    Frankfurt, 60596, Germany
  • Velocity Clinical Research Germany GmbH
    Großhansdorf, 22927, Germany
  • Lungenfachklinik Immenhausen
    Immenhausen, 34376, Germany
  • Klinikum Konstanz
    Konstanz, 78464, Germany
  • Velocity Clinical Research Germany GmbH
    Lübeck, 23552, Germany
  • Klinikum der Universität München - Campus Innenstadt
    München, 80336, Germany
  • Velocity Clinical Research Germany GmbH
    Wiesbaden, 65189, Germany
  • Univ. Gen. Hosp. of Ioannina
    Ioannina, 45 500, Greece
  • Semmelweis University
    Budapest, 1083, Hungary
  • Da Vinci Private Clinic
    Pécs, 7635, Hungary
  • Soroka Univ. Medical Center
    Beersheba, 8410101, Israel
  • Lady Davis Carmel Medical Center
    Haifa, 3436212, Israel
  • Hadassah Medical Center, Ein-Karem
    Jerusalem, 9112001, Israel
  • Sourasky Medical Center
    Tel Aviv, 6093246, Israel
  • A.O. Univ. Policlinico "Paolo Giaccone"
    Palermo, 90127, Italy
  • Fondazione IRCCS Policlinico S. Matteo
    Pavia, 27100, Italy
  • Istituto Clinico Humanitas
    Rozzano (MI), 20089, Italy
  • Nagoya University Hospital
    Aichi, Nagoya, 466-8560, Japan
  • Hirosaki University Hospital
    Aomori, Hirosaki, 036-8563, Japan
  • Kameda Clinic
    Chiba, Kamogawa, 296-0041, Japan
  • Kyushu University Hospital
    Fukuoka, Fukuoka, 812-8582, Japan
  • Fukuoka University Hospital
    Fukuoka, Fukuoka, 814-0180, Japan
  • Ibarakihigashi National Hospial
    Ibaraki, Naka-gun, 319-1113, Japan
  • Kagoshima University Hospital
    Kagoshima, Kagoshima, 890-8520, Japan
  • Matsusaka City Hospital
    Mie, Matsusaka, 515-8544, Japan
  • Niigata University Medical and Dental Hospital
    Niigata, Niigata, 951-8520, Japan
  • Osaka Toneyama Medical Center
    Osaka, Toyonaka, 560-8552, Japan
  • Saga University Hospital
    Saga, Saga, 849-8501, Japan
  • Fukujuji Hospital
    Tokyo, Kiyose, 204-8522, Japan
  • Kitasato Institute Hospital
    Tokyo, Minato-ku, 108-8642, Japan
  • Daugavpils Regional Hospital LTD Centre Outpatient Clinic
    Daugavpils, 5401, Latvia
  • Med.Center OLVI Health Center Assotiation,Private Practice
    Daugavpils, 5410, Latvia
  • VCA Dubultu Medical center
    Jūrmala, 2015, Latvia
  • Riga 1st Hospital
    Riga, 1001, Latvia
  • Pauls Stradins Clinical University Hospital
    Riga, 1002, Latvia
  • LUMPII Doctors practice
    Riga, 1011, Latvia
  • Mediadvance Clinical S.A.P.I de C.V.
    Chihuahua City, 31203, Mexico
  • Accelerium S de RL de CV
    Monterrey, 64000, Mexico
  • Hospital Universitario Nuevo de Nuevo León - CEPREP
    Monterrey, Nuevo León, C.P. 64460, Mexico
  • Hospital Universitario Dr Jose Eleuterio Gonzalez
    Nuevo León, 64460, Mexico
  • Oaxaca Site Management Organization, S.C.
    Oaxaca City, 68000, Mexico
  • Clinical Research Institute S.C.
    Tlalnepantla, 54055, Mexico
  • Amsterdam UMC, location VUMC
    Amsterdam, 1081 HV, Netherlands
  • Gelre Ziekenhuis Zutphen
    Zutphen, 7207 AE, Netherlands
  • Respiratory Medicine Centre, private prac., Bialystok
    Bialystok, 15044, Poland
  • Screenmed Sp. z o.o.
    Piaseczno, 05500, Poland
  • Alergopneuma Medical Center
    Świdnik, 21040, Poland
  • Altamed Specjalistyczna Praktyka Lekarska Pawel Siwinski
    Warsaw, 01-456, Poland
  • Dr. Piotr Napora, Center of Clinical Research
    Wroclaw, 51162, Poland
  • ULS de Santa Maria, E.P.E
    Lisbon, 1064-035, Portugal
  • Chungbuk National University Hospital
    Cheongju-si, 28644, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Korea University Guro Hospital
    Seoul, 08308, South Korea
  • SMG-SNU Boramae Medical Center
    Seoul, 156-707, South Korea

Showing the first 100 of 112 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Chalmers JD, Shteinberg M, Mall MA, O'Donnell AE, Watz H, Gupta A, Frahm E, Eleftheraki A, Rauch J, Chotirmall SH, Armstrong AW, Eickholz P, Hasegawa N, Sauter W, McShane PJ. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study. Eur Respir J. 2025 Jan 2;65(1):2401551. doi: 10.1183/13993003.01551-2024. Print 2025 Jan. PubMed 39255990 ↗
  • Badorrek P, Diefenbach C, Kogler H, Eleftheraki A, Seitz F, Hohlfeld JM. Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers. Clin Transl Sci. 2024 Aug;17(8):e13891. doi: 10.1111/cts.13891. PubMed 39175217 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in May 2024, 24 months.

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2022
First posted
Feb 14, 2022
StartActual
Apr 28, 2022
Primary completionActual
May 1, 2024
CompletionActual
May 30, 2024
Results delay requested
Apr 29, 2025
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05238675
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
Apr 28, 2022
Primary completion
May 1, 2024
Completion
May 30, 2024
Last update
Jul 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verducatib

Start the discussion